Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1949 2
1950 2
1951 1
1953 1
1954 3
1962 1
1963 18
1965 1
1967 1
1969 1
1971 1
1972 1
1975 1
1976 1
1979 2
1982 1
1983 1
1986 1
1987 1
1988 3
1989 3
1990 1
1993 1
1997 2
1999 3
2001 2
2003 1
2006 3
2007 5
2008 1
2009 7
2010 9
2011 10
2012 11
2013 11
2014 10
2015 11
2016 7
2017 9
2018 5
2019 6
2020 3
2021 7
2022 23
2023 15
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
CRASH-2 trial collaborators; Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejía-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S. CRASH-2 trial collaborators, et al. Lancet. 2010 Jul 3;376(9734):23-32. doi: 10.1016/S0140-6736(10)60835-5. Epub 2010 Jun 14. Lancet. 2010. PMID: 20554319 Clinical Trial.
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
CRASH-2 collaborators; Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. CRASH-2 collaborators, et al. Lancet. 2011 Mar 26;377(9771):1096-101, 1101.e1-2. doi: 10.1016/S0140-6736(11)60278-X. Lancet. 2011. PMID: 21439633 Clinical Trial.
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. Among authors: ben nasr h. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462
Terbinafine induced pancreatitis in a healthy young adult male.
Brydges HT, Onuh OC, Nasr HY, Gonda TA, Chiu ES, Caplan AS. Brydges HT, et al. Among authors: nasr hy. Dermatol Ther. 2022 Aug;35(8):e15604. doi: 10.1111/dth.15604. Epub 2022 Jun 8. Dermatol Ther. 2022. PMID: 35620915 No abstract available.
[The therapeutic contribution of proteomic approaches in cancers].
Hamrita B, Nasr HB, Kabbage M, Hamann P, Kuhn L, Guillier C, Remadi S, Chaieb A, Khairi H, Chouchane L, Chahed K. Hamrita B, et al. Among authors: nasr hb. Gynecol Obstet Fertil. 2011 Feb;39(2):87-93. doi: 10.1016/j.gyobfe.2010.12.005. Epub 2011 Feb 12. Gynecol Obstet Fertil. 2011. PMID: 21317010 Review. French.
Bone and bone substitutes.
Nasr HF, Aichelmann-Reidy ME, Yukna RA. Nasr HF, et al. Periodontol 2000. 1999 Feb;19:74-86. doi: 10.1111/j.1600-0757.1999.tb00148.x. Periodontol 2000. 1999. PMID: 10321217 Review.
190 results